Repositioning Candidate Details
| Candidate ID: | R1005 |
| Source ID: | DB06405 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Eprodisate |
| Synonyms: | 1,3-propanedisulfonic acid; Eprodisate; Propane-1,3-disulfonate; Propane-1,3-disulfonic acid; Propane-1,3-disulphonate |
| Molecular Formula: | C3H8O6S2 |
| SMILES: | OS(=O)(=O)CCCS(O)(=O)=O |
| Structure: |
|
| DrugBank Description: | Eprodisate slows the decline of renal function in AA amyloidosis. |
| CAS Number: | 21668-77-9 |
| Molecular Weight: | 204.21 |
| DrugBank Indication: | Investigated for use/treatment in amyloidosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Decline in renal function associated with Amyloid A (AA) amyloidosis can be slowed by eprodisate (Kiacta), a drug that inhibits the deposit of the complex protein in tissues. AA amyloidosis is a serious, frequently fatal disorder involving deposits of amyloid fibrils in various organs and tissues. It is a complication of many chronic inflammatory disorders, but little is known about its etiology or natural history. Eprodisate delays the progression of AA amyloidosis-associated renal disease. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|